INNOVIVE Pharmaceuticals Begins Enrollment In Phase I Study Of INNO-305 Peptide Immunotherapy In AML, MDS, Mesothelioma And Non-Small Cell Lung Cancer

NEW YORK--(BUSINESS WIRE)--INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH), a biopharmaceutical company headquartered in Manhattan, announced today that a Phase I clinical trial investigating INNO-305 in acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), mesothelioma and non-small cell lung cancer (NSCLC) has enrolled its first patient. The trial is being conducted by Lee Krug, M.D., of the Thoracic Oncology Service, and Peter Maslak, M.D., of the Leukemia Service at Memorial Sloan Kettering Cancer Center in New York.

MORE ON THIS TOPIC